Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Soft tissue chondroma (extraskeletal chondroma) of the hand: Report of three cases.

Radiology case reports·2026
Same author

PEPN1924, A Phase II Study of Trastuzumab Deruxtecan in Patients With Recurrent Human Epidermal Growth Factor Receptor 2+ Osteosarcoma: A Children's Oncology Group Pediatric Early-Phase Clinical Trial Network Study.

JCO oncology advances·2026
Same author

Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic Toxicity.

JCO precision oncology·2026
Same author

Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Spatially-resolved single cell atlas of liposarcoma reveals lineage hierarchies, immune niches, and regulatory circuits.

bioRxiv : the preprint server for biology·2026
Same author

Deceptive Thyroid Pathologies: Anaplastic Thyroid Carcinoma Mimics and Clinical Implications.

Head & neck·2026
Same journal

Next-Generation Checkpoint Combinations: Optimizing PD-(L)1-Based Therapy Across the Advanced, Adjuvant, and Neoadjuvant Settings.

Current oncology reports·2026
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
See all related articles

Related Experiment Video

Updated: Mar 14, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

8.8K

Uterine Adenosarcoma: a Review.

Michael J Nathenson1, Vinod Ravi2, Nicole Fleming3

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA. mjnathenson@gmail.com.

Current Oncology Reports
|October 9, 2016
PubMed
Summary
This summary is machine-generated.

Uterine adenosarcomas are rare tumors with a benign epithelial and malignant mesenchymal component. Standard treatment is hysterectomy, with survival impacted by factors like sarcomatous overgrowth.

Keywords:
AdenosarcomaOvarianReviewSarcomaSoft tissue sarcomaUterine

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.4K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

4.4K

Related Experiment Videos

Last Updated: Mar 14, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

8.8K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.4K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

4.4K

Area of Science:

  • Gynecologic Oncology
  • Pathology
  • Rare Cancers

Background:

  • Adenosarcomas are rare uterine malignancies, comprising ~5% of uterine sarcomas.
  • Characterized by benign epithelial and malignant mesenchymal elements, diagnosis relies on morphology.
  • Commonly present with abnormal uterine bleeding, often diagnosed at Stage I.

Purpose of the Study:

  • To review the current understanding of uterine adenosarcoma.
  • To discuss the diagnosis and management of this rare tumor.

Main Methods:

  • Review of current literature on uterine adenosarcoma.
  • Analysis of diagnostic criteria, prognostic factors, and treatment outcomes.

Main Results:

  • 5-year survival is 60-80%, influenced by myometrial invasion, sarcomatous overgrowth, and heterologous elements.
  • Sarcomatous overgrowth significantly increases recurrence risk and decreases survival.
  • Standard treatment involves hysterectomy with bilateral salpingo-oophorectomy; adjuvant radiotherapy or chemotherapy lack proven benefit.

Conclusions:

  • Uterine adenosarcoma management requires careful consideration of prognostic factors.
  • The PIK3/AKT/PTEN pathway mutations present a potential therapeutic target.
  • Further research is needed to establish optimal adjuvant therapies.